Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;397(12):9227-9241.
doi: 10.1007/s00210-024-03258-6. Epub 2024 Jul 2.

Mapping the landscape: a bibliometric study of global chimeric antigen receptor T cell immunotherapy research

Affiliations
Review

Mapping the landscape: a bibliometric study of global chimeric antigen receptor T cell immunotherapy research

Wenhao Zhang et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 Dec.

Abstract

The rise of immunotherapy provided new approaches to cancer treatment. We aimed to describe the contribution of chimeric antigen receptor T cell immunotherapy to future prospects. We analyzed 8035 articles from the Web of Science Core Collection with CiteSpace that covered with various aspects with countries, institutions, authors, co-cited authors, journals, keywords, and references. The USA was the most prolific country, with the University of Pennsylvania being the most published institution. Among individual authors, June Carl H published the most articles, while Maude SL was the most frequently co-cited author. "Blood" emerged as the most cited journal. Keyword clustering revealed six core themes: "Expression," "Chimeric Antigen Receptor," "Tumor Microenvironment," "Blinatumomab," "Multiple Myeloma," and "Cytokine Release Syndrome." In the process of researching the timeline chart of keywords and references, "Large B-cell lymphoma" was located on the right side of the timeline. In the keyword prominence analysis, we found that the keywords "biomarkers," "pd-1," "antibody drug conjugate," "BCMA," and "chimeric antigen" had high explosive intensity in the recent past. We found that in terms of related diseases, "large B-cell lymphoma" and "cytokine release syndrome" are still difficult problems in the future. In the study of therapeutic methods, "BCMA," "PD-1," "chimeric antigen," and "antibody drug conjugate" deserve more attention from researchers in the future.

Keywords: Bibliometric analysis; Cancer; Chimeric antigen receptor T cell immunotherapy; CiteSpace.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval: No ethical approval was required for all analyses. Consent to participate: Informed consent was obtained from all individual participants included in the study. Consent for publication: The authors affirm that human research participants provided informed consent for publication. Competing interests: The authors declare no competing interests.

Similar articles

References

    1. Abbott M, Ustoyev Y (2019) Cancer and the immune system: the history and background of immunotherapy. Semin Oncol Nurs 35:150923. https://doi.org/10.1016/j.soncn.2019.08.002 - DOI - PubMed
    1. Alfouzan AF (2021) Radiation therapy in head and neck cancer. Saudi Med J 42:247–254. https://doi.org/10.15537/smj.2021.42.3.20210660 - DOI - PubMed - PMC
    1. Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, Beauvais D, Roulin L, Gros FX, Rubio MT, Bories P, Bay JO, Llorente CC, Choquet S, Casasnovas RO, Mohty M, Guidez S, Joris M, Loschi M, Carras S, Abraham J, Chauchet A, Drieu La Rochelle L, Deau-Fischer B, Hermine O, Gastinne T, Tudesq JJ, Gat E, Broussais F, Thieblemont C, Houot R, Morschhauser F (2022) A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med 28:2145–2154. https://doi.org/10.1038/s41591-022-01969-y - DOI - PubMed - PMC
    1. Baker DJ, Arany Z, Baur JA, Epstein JA, June CH (2023) CAR T therapy beyond cancer: the evolution of a living drug. Nature 619:707–715. https://doi.org/10.1038/s41586-023-06243-w - DOI - PubMed
    1. Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S (2019) Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci 20. https://doi.org/10.3390/ijms20061283

Publication types

Substances

LinkOut - more resources